Publications:

AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.

Nature Communications

Kim, Dae Gyu DG; Choi, Yongseok Y; Lee, Yuno Y; Lim, Semi S; Kong, Jiwon J; Song, JaeHa J; Roh, Younah Y; Harmalkar, Dipesh S DS; Lee, Kwanshik K; Goo, Ja-Il JI; Cho, Hye Young HY; Mushtaq, Ameeq Ul AU; Lee, Jihye J; Park, Song Hwa SH; Kim, Doyeun D; Min, Byung Soh BS; Lee, Kang Young KY; Jeon, Young Ho YH; Lee, Sunkyung S; Lee, Kyeong K; Kim, Sunghoon S

Publication Date: 2022-05-11

Variant appearance in text: KRAS: Q43A

PubMed Link: 35546148

Variant Present in the following documents:

• 41467_2022_30149_MOESM1_ESM.pdf

View BVdb publication page

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation.

Nature Communications

Tran, Timothy H TH; Chan, Albert H AH; Young, Lucy C LC; Bindu, Lakshman L; Neale, Chris C; Messing, Simon S; Dharmaiah, Srisathiyanarayanan S; Taylor, Troy T; Denson, John-Paul JP; Esposito, Dominic D; Nissley, Dwight V DV; Stephen, Andrew G AG; McCormick, Frank F; Simanshu, Dhirendra K DK

Publication Date: 2021-02-19

Variant appearance in text: KRAS: Q43A

PubMed Link: 33608534

Variant Present in the following documents:

• Main text
• 41467_2021_21422_MOESM4_ESM.xlsx, sheet 7
• 41467_2021_Article_21422.pdf
• 41467_2021_21422_MOESM1_ESM.pdf
• 41467_2021_21422_MOESM4_ESM.xlsx, sheet 4

View BVdb publication page